Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.
1
Study Matches
A prospective, multi-national, non-interventional study in haemophilia A and B patients with or without inhibitors treated according to routine clinical treatment practice (explorer™6)
A non-interventional study designed to prospectively collect
comprehensive data on bleeding episodes and health-related quality of life as well as on physical activity in patients with severe congenital haemophilia A (HA) and B (HB), with or without inhibitors under routine local clinical practice, irrespective of the treatment regimen.
age ≥ 12 years Severe (< 1%) congenital hemophilia A or B with or without inhibitors Pts with inhibitors treated on-demand: ≥ 6 treated (with bypassing agent) bleeding episodes within 24 wks of screening Pts with severe congenital HA/HB treated on-demand: ≥ 5 treated (with factor product) bleeding episodes within 24 wks of screening Pts with inhibitors treated with FEIBA prophylaxis: ≥ 2 treated bleeding episodes within 24 wks of screening
Exclusion Criteria:
Known or suspected hypersensitivity to monoclonal antibodies Previous treatment with concizumabdefined as two or more doses administered. Planned FVIII/FIX Immune Tolerance Induction (ITI) regimens during the study. Current or planned treatment with emicizumab. Any known congenital or acquired coagulation disorder other than congenital hemophilia.